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Edited by Veli-Pekka LehtoAbstract PDGFR inhibitors are successfully used in a number
of cancer treatments. The standard treatment for acute promye-
locytic leukemia (APL) involves diﬀerentiation therapy with ret-
inoic acid (RA). However, the relapse rates are signiﬁcant. In the
present work we evaluated the eﬀects of RA therapy in the pres-
ence of PDGFR inhibitor, AG1296. Adding AG1296 with RA in-
creased secretion of TNF-a, IL-8, and MMP-9 expression. This
treatment induced higher levels of ICAM-1 endothelial cell
expression, and increased cellular mobility. Inhibiting PDGFR
enhanced RA-induced expression of integrin. Integrin ligand in-
creased diﬀerentiation markers CD11b, inducible oxidative
metabolism and PDGFR-b phosphorylation. While the neutro-
phil–endothelial cell interactions are strengthened by the com-
bined treatment, the endothelium-substratum interactions are
weakened, a situation common in RAS.
 2008 Federation of European Biochemical Societies. Pub-
lished by Elsevier B.V. All rights reserved.
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The standard clinical treatment of acute promyelocytic leu-
kemia (APL) is diﬀerentiation induction therapy using all
trans-retinoic acid (RA). Diﬀerentiation therapy results in phe-
notypic conversion of promyelocytic cells into mature neutro-
phils. This conversion is characterized by CD38 and CD11b
expression, cell cycle arrest in G0 and ability of mature neutro-
phils to perform a respiratory burst. RA treatment results in
complete remission in 92–95% of patients [1]. However, this
therapeutic approach has several limitations such as the devel-
opment of resistance to RA, retinoic acid syndrome (RAS) or
hyperleukocytosis [2]. RAS, also known as APL diﬀerentiation
syndrome, currently occurs in 10–15% of patients and is fatal
in approximately 10% of them [3]. It is caused by the RA-med-
iated conversion of APL blast cells to mature neutrophils.
These neutrophils are abundant and express cytokines, such
as interleukin (IL)-1b, IL-8, interferon-c (INF-c) and tumor
necrosis factor-a (TNF-a) [4]. Endothelial cells are exposed
to these cytokines in the blood stream and respond by express-
ing adhesion molecules which subsequently facilitate the bind-
ing of neutrophils to endothelial cells (reviewed in [5]) and by
increasing the endothelial cells mobility leading to increased
leukocyte inﬁltration and lung capillary leak. CD11b expressed*Corresponding author. Fax: +1 607 253 3317.
E-mail address: ay13@cornell.edu (A. Yen).
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endothelial cells expressing ICAM. Neutrophils migrate
through the endothelium by expressing extracellular matrix
degrading enzymes, such as matrix metallo-proteinases
(MMPs), and increasing their motility on and through endo-
thelial cells via cytoskeletal rearrangements that are triggered
by signals from the focal adhesion kinase (FAK) upon adhe-
sion [6]. This process leads to the impairment of the endothelial
barrier with leukocyte inﬁltration characterizing the cardio-
pulmonary distress during RAS.
HL-60 cells are human myeloblastic leukemia cells that serve
as a model for studying diﬀerentiation induction therapy [7].
These cells undergo growth arrest and myeloid diﬀerentiation
in response to RA [8]. We have recently reported that
AG1296, a potent and selective inhibitor for PDGFR and its
family members, Kit and Flt3 [9], enhances various facets of
both RA induced myeloid diﬀerentiation, including inducible
oxidative metabolism [10]. However, other features typical of
these induced diﬀerentiation programs were diminished,
including induced G0 cell cycle arrest. Because we observed
that PDGFR inhibition during RA induced diﬀerentiation re-
sulted in increased adherence of cells to tissue culture surfaces
and an increase in CD11b expression, which is a cell surface
molecule that heterodimerizes with the integrin receptor, we
hypothesized that the eﬀect of AG1296 on diﬀerentiation was
partly mediated by the cross talk of the PDGFR with the inte-
grin receptor and might have implications during RAS.
To achieve a higher rate of complete remission in clinical
treatment of APL, RA is administered in combination with
chemotherapy [3]. However, the impact of the drug–drug inter-
action on RAS is unclear. Here, we report that the presence of
the platelet derived growth factor receptor (PDGFR) inhibitor
AG1296 during RA-induced myeloid diﬀerentiation results in
neutrophils that excrete higher levels of IL-8 and TNF-a, ex-
press higher levels of MMP-9 and subsequently induce higher
levels of ICAM-1 expression on endothelial cells. The results of
this study suggest a higher risk for RAS in patients that receive
PDGFR inhibitors during diﬀerentiation induction therapy
and that the PDGFR is involved in suppressing features that
contribute to RAS. The ﬁndings also suggest a potential in vi-
tro model for RAS.2. Materials and methods
2.1. Cell culture
HL-60 human myeloblastic leukemia cells and EAhy 926 human
macrovascular endothelial cells were grown in RPMI 1640 and
DMEM, respectively. Media were supplemented with 5% heat-inacti-blished by Elsevier B.V. All rights reserved.
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biotic/antimicotic (Sigma, St. Louis, MO) in a 5% CO2 humidiﬁed
atmosphere at 37 C. RA (Sigma) was added from a 0.5 mM stock
solution in ethanol with a ﬁnal concentration of 2 lM in culture.
AG1296 and integrin aMb2 ligand stabilizing integrin aMb2 in its
active state [11] (Calbiochem, La Jolla, CA) were added as carrier
blanks to cell cultures at the same time as RA treatment at a concen-
tration of 10 lM from stock solutions (20 mM) in DMSO. Equal
amounts of DMSO were added to all treatment groups not receiving
AG1296 or integrin ligand. Experimental cultures were initiated at a
density of 0.2 · 106 cells/ml. Viability was monitored by 0.2% trypan
blue (Invitrogen) exclusion and routinely exceeded 95% throughout
the time frame of the experiments.2.2. CD11b, CD18, CD38, MMP-9, and pPDGFR-b expression studies
0.5 · 106 cells were collected from cultures and centrifuged at
1000 rpm in a microfuge for 5 min. Cell pellets were resuspended in
100 ll 37 C PBS containing 5 ll of the respective antibody (APC con-
jugated CD11b, FITC conjugated CD18, PE conjugated CD38 all
from BD Biosciences, San Jose, CA). Following 1 h incubation at
37 C cell surface expression levels were analyzed with a BD LSRII
ﬂow cytometer (BD Biosciences). To stain for MMP-9, PDGFR
pY1021 we used primary antibodies from Biovision, Mountain View,
CA, Cell Signaling, Danvers, MA, and Santa Cruz Biotechnology,
CA, respectively. 0.5 · 106 cells were collected from cultures and cen-
trifuged at 1000 rpm in a microfuge for 5 min, ﬁxed, and permeabilized
by resuspension of the pellet in 100 ll 2% paraformaldehyde in PBS for
10 min at room temperature followed by the addition of 900 ll 100%
ice cold methanol to obtain a 90% methanol solution. Following an
incubation for 20 min at 20 C samples were washed two times in
PBS and resuspended in 100 ll PBS containing 1 ll of respective pri-
mary antibody. Following a 1 h incubation period cells were washed
once with 1 ml PBS and staining with secondary FITC-conjugated
anti-rabbit antibody (BD Biosciences) for 1 h and analyzed by ﬂow
cytometry. For CD11b, CD18, and CD38 undiﬀerentiated control cells
were used to determine the ﬂuorescence intensity of cells negative for
the respective surface antigen. The gate to determine percent increase
of expression was set to exclude 95% of the control population. Results
for MMP-9, and pPDGFR-b are given as mean ﬂuorescence intensity
as determined by quantifying the ﬂuorescence intensity of the entire
cell population sample (30000 cells) by ﬂow cytometry. Cells unstained
with the primary antibody but incubated with the secondary antibody
were used to generate the background signal.2.3. Measurement of inducible oxidative metabolism
0.5 · 106 cells were collected and centrifuged at 1000 rpm for 5 min
in a microfuge. Cell pellets were resuspended in 200 ll 37 C PBS con-
taining 5 lM 5-(and-6)-chloromethyl-2 0,7 0-dichlorodihydro-ﬂuorescein
diacetate acetyl ester (H2-DCF, Molecular Probes, Eugene, OR) and
0.2 lg/ml 12-o-tetradecanoylphorbol-13-acetate (TPA, Sigma). Both,
H2-DCF and TPA stock solutions were made in DMSO at concentra-
tions of 0.2 mg/ml and 5 mM, respectively. A control group incubated
in H2-DCF and DMSO only was included. Cells were incubated for
20 min at 37 C prior to analysis by ﬂow cytometry. Oxidized DCF
was excited by a 488 nm laser and emission collected through a 505
long pass dichroic mirror and a 530/30 nm band pass ﬁlter. The shift
in ﬂuorescence intensity in response to TPA was used to determine
the percent cells with the capability to generate inducible oxidative
metabolites. Gates to determine percent positive cells were set to ex-
clude 95% of control cells not stimulated with TPA.2.4. TNF-a and IL-8 secretion
Cells were treated or not with 2 lM RA plus or minus AG1296 for
72 h. Two million cells were pelleted and resuspended in fresh cell cul-
ture media to account for cell treatment groups growing at slightly dif-
ferent rates. After 5 h cells were pelleted again and the cell culture
media was stored at 80 C until further analysis. ELISAs were per-
formed according to the manufacturers instructions of ELISA
MAX Set Standard reagent sets for human TNF-a and human IL-
8 (BioLegend, San Diego, CA). We used 100 ll of collected media
for TNF-a and 10 ll for IL-8 analyses. HRP-mediated conversion of
TMB substrate (BioLegend) was determined reading absorbance at
450 nm using a plate reader (BioRad 680). Values obtained from opti-cal absorbance were converted to values in pg/ml using the optical
absorbances obtained from standards with known concentrations.
2.5. ICAM-1 expression on endothelial cells and endothelial cell
migration
To determine cytotoxic eﬀects of neutrophils on endothelial cells we
grew endothelial cells for 3 days in six well plates to form a 90% con-
ﬂuent endothelial cell layer. Endothelial cells were subsequently ex-
posed to 2 million HL-60 cells in 2 ml of fresh cell culture media.
HL-60 cells had been treated or not with 2 lM RA for 72 h plus or
minus 10 lM AG1296. After 24 h of co-culturing endothelial and
HL-60 cells, endothelial cells were collected using an enzyme-free cell
dissociation buﬀer (Invitrogen). For the ICAM expression, equal
amounts of cells were stained with APC-conjugated ICAM-1 (BioLeg-
end) and PE-conjugated endothelial cell marker CD144 to distinguish
between endothelial and HL-60 cells (eBioscience, San Diego, CA).
Cells were analyzed using a BD Biosciences LSRII ﬂow cytometer.
Only cells staining positive for CD144 were included in the quantiﬁca-
tion of ICAM-1.
A characteristic of RAS is the weakening of the endothelial cell–cell
and cell–substratum interactions. In order to assess these phenomena,
an endothelial cell migration assay (wounding assay) was performed.
Conﬂuent endothelial cell monolayers (in six well plates) were
wounded with a pipette tip, each well was washed with PBS and then
the HL-60 cells were added as described above. After 24 h of coculture,
the cell suspension was removed, the monolayer was washed with PBS
and the pictures were taken. Cells that had migrated to the wounded
areas were counted for quantiﬁcation of cell migration.
2.6. Statistical analysis
Statistical analyses were performed using SPSS 11.0 for Windows,
Student Edition. Means of treatment groups of interest were compared
using the Paired-Samples t-test. All treatment groups were com-
pared to control cells. The eﬀect of AG1296 was determined by
comparing groups receiving RA with groups receiving RA plus
AG1296. A P-value of <0.05 was considered signiﬁcant.3. Results
3.1. AG1296 treated HL-60 undergoing myeloid diﬀerentiation
have enhanced secretion of TNF-a and IL-8 and increased
expression of MMP-9
During RAS neutrophils elicit their cytotoxic eﬀects by
releasing cytokines such as TNF-a and IL-8. In addition, neu-
trophils express extracellular matrix degrading enzymes, such
as metalloproteinase-9 (MMP-9) to facilitate their invasion
into subendothelial tissues.
We quantiﬁed TNF-a and IL-8 secretion of HL-60 cells trea-
ted for 72 h with RA plus and minus AG1296. RA treated cells
showed signiﬁcantly increased TNF-a (P = 0.034; Fig. 1A) and
IL-8 (P = 0.009; Fig. 1B) secretion. When cells received
AG1296 in addition to RA we found a signiﬁcant increase in
TNF-a (P = 0.012) and IL-8 (P = 0.001) secretion when com-
pared to cells receiving RA alone and when compared to con-
trol cells (P < 0.010).
MMP-9 expression was measured in cells treated for 72 h
with RA plus or minus AG1296. We separated cells in sus-
pension from adherent cells as MMP-9 is predominantly ex-
pressed in adherent cells. We have determined previously
[10] that AG1296 causes a higher percentage of diﬀerentiated
HL-60 cells to adhere to substrates and hence we wanted to
account for that diﬀerence by separating suspension from
adhering cells rather than taking a pooled sample. Cells trea-
ted with RA plus AG1296 that adhered to substrate 72 h
post-treatment had signiﬁcantly (P = 0.029) higher MMP-9
protein expression compared to adherent cells treated with
RA alone (Fig. 1C). Suspension cells that were diﬀerentiated
Fig. 1. AG1296 increases the secretion of TNF-a and IL-8, and MMP-9 protein expression in myeloid diﬀerentiated HL-60 cells. TNF-a (A) and IL-
8 (B) secretion was determined by ELISA from cells that were treated or not with RA plus or minus 10 lMAG1296 for 72 h. MMP-9 (C) expression
was determined by ﬂow cytometry following 72 h RA-meditated myeloid diﬀerentiation in the absence or presence of 10 lM AG1296. Shown are
means with error bars representing standard errors of means from three independent experiments. The insert shows MMP-9 histograms for a typical
experiment. (*) indicates treatment groups that were signiﬁcantly diﬀerent from control and (#) indicates RA plus AG1296 treated groups that were
signiﬁcantly diﬀerent from cells receiving RA only. C, control; A, 10 lM AG1296; R, 2 lM retinoic acid; R + A, 10 lM AG1296 plus 2 lM retinoic
acid; R sus, retinoic acid treated suspension cells; R adh, retinoic acid treated adherent cells; R + A sus, retinoic acid plus AG1296 treated suspension
cells; RA adh, retinoic acid plus AG1296 treated adherent cells.
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sion above control levels.
These data suggest that inhibiting the PDGFR during
RA-mediated diﬀerentiation results in neutrophils that are
potentially more cytotoxic to endothelial cells and could hence
increase the risk of resulting in RAS.Fig. 2. HL-60 cells treated with AG1296 during myeloid diﬀerentia-
tion induce ICAM-1 expression in endothelial cells. HL-60 cells were
treated with RA in the absence or presence of 10 lMAG1296 for 72 h.
A total of 2 million HL-60 cells in 2 ml of media were pipetted on a
monolayer of EAhy926 endothelial cells that were grown in a six well
plate for 72 h. Following 24 h of co-culture both cell types were
removed from the culture dish and stained with ICAM-1 and
endothelial cell marker CD144 to distinguish the two cell types. Error
bars representing standard errors of means from six independent
experiments. The insert shows ICAM-1 histograms for a typical
experiment. (*) indicates treatment groups that were signiﬁcantly
diﬀerent from control and (#) indicates RA plus AG1296 treated
groups that were signiﬁcantly diﬀerent from cells receiving RA only. C,
control; A, 10 lM AG1296; R, 2 lM retinoic acid; R + A, 10 lM
AG1296 plus 2 lM retinoic acid.3.2. HL-60 cells treated with AG1296 during myeloid
diﬀerentiation induce higher ICAM-1 levels in endothelial
cells
Because the AG1296 mediated increase in TNF-a and IL8
secretion and MMP-9 expression suggested increased cytotoxic
eﬀects, we aimed to determine endothelial cell activation after
exposure to HL-60 cells. When endothelial cells grown to form
a monolayer for 72 h were exposed for 24 h to undiﬀerentiated
HL-60 cells (untreated control HL-60 cells and AG1296 trea-
ted HL-60 cells), endothelial cells did not express ICAM-1 sig-
niﬁcantly above endothelial cells that had not been exposed to
HL-60 cells (Fig. 2). However, HL-60 cells, induced to diﬀeren-
tiate for 72 h with RA, induced ICAM-1 expression in 30.02%
endothelial cells. HL-60 cells induced to diﬀerentiate by treat-
ing for 72 h with RA plus AG1296 induced ICAM-1 expres-
sion in 48.88% endothelial cells which was signiﬁcantly
higher than in endothelial cells exposed to HL-60 cells treated
with RA alone (P = 0.0003).
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involved in mediating the migration of neutrophils into sub-
endothelial tissues [5]. AG1296 treatment during myeloid
diﬀerentiation might therefore lead to enhanced migration of
neutrophils through the endothelial barrier.
3.3. Stabilizing integrin 2 aMb2 had similar eﬀects on
diﬀerentiation as AG1296
Because the PDGFR inhibitor AG1296 caused adhesion, we
suspected integrins, molecules that mediate cell adhesion, may
mediate some of the eﬀects we observed using AG1296 during
myeloid diﬀerentiation. To evaluate the role of integrins during
myeloid diﬀerentiation of HL-60 cells, we used an integrin li-
gand that stabilizes the active form of integrin aMb2 by bind-
ing to its intracellular domain. Cells that were treated with RA
plus integrin ligand had slightly lower CD38 expression afterFig. 3. HL-60 cells treated with integrin aMb2 ligand during myeloid diﬀere
were treated or not with RA plus or minus integrin ligand for 24 h, 48 h, and 7
were decreased in cells treated with RA plus integrin ligand when compared
capability of oxidative metabolism at 48 h (D) were increased in cells treated
alone. Shown are means with error bars representing standard errors of
histograms (panel A), DNA histograms (panel B), CD11b histograms (pane
signiﬁcantly diﬀerent from control and (#) indicates RA plus AG1296 treated
control; L, 5 lM integrin aMb2 ligand; R, 2 lM retinoic acid; R + L, 5 lM24 h when compared to cells that received RA only (Fig.
3A). CD38 is the earliest marker of diﬀerentiation along the
neutrophil lineage. 72 h co-treatment of HL-60 cells with RA
and integrin ligand signiﬁcantly (P = 0.0238) reduced the in-
duced G0 arrest when compared to cells treated with RA alone
(Fig. 3B). In contrast, CD11b expression after 48 h was signif-
icantly (P = 0.032) higher in cells that were treated with RA
plus integrin ligand when compared to cells that were treated
with RA alone (Fig. 3C). The integrin ligand also signiﬁcantly
(P = 0.023) enhanced RA-induced capability for inducible oxi-
dative metabolism compared to cells that received only RA for
48 h (Fig. 3D). The mature neutrophils are characterized by
ability to perform inducible oxidative metabolism.
These data revealed that the integrin ligand had the same ef-
fect on diﬀerentiation markers as AG1296 has, namely an in-
crease in CD11b and oxidative metabolism. This furtherntiation have enhanced features of myeloid diﬀerentiation. HL-60 cells
2 h, respectively. CD38 expression at 24 h (A) and G0 arrest at 72 h (B)
to cells treated with RA alone. CD11b (C) expression at 48 h and the
with RA plus integrin ligand when compared to cells treated with RA
means from three independent experiments. The insert shows CD38
l C) for a typical experiment. (*) indicates treatment groups that were
groups that were signiﬁcantly diﬀerent from cells receiving RA only. C,
integrin aMb2 ligand plus 2 lM retinoic acid.
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inhibitor AG1296 were mediated through adhesion molecules
such as integrin aMb2 and points to a negative cross talk be-
tween PDGFR and integrin regulated pathways.
3.4. AG1296 increases CD18 expression and integrin 2 aMb2
ligand enhances PDGFR-b phosphorylation
Since using a PDGFR inhibitor or an integrin ligand re-
sulted in the same outcome in regards to myeloid diﬀerentia-
tion we decided to further investigate a possible negative
crosstalk between PDGFR and integrin. When we measured
integrin b2 expression in RA treated HL-60 cells receiving
AG1296 during diﬀerentiation we found integrin expression
to be signiﬁcantly increased (P = 0.0147) compared to cells
that received RA alone (Fig. 4A). However, when cells were
treated with the integrin ligand in addition to RA, PDGFR-
b phosphorylation was enhanced at Y1021 activation site when
compared to cells that were treated with RA alone (Fig. 4B).
These data show that a potential negative crosstalk between
the PDGF and integrin receptors is not reciprocal. Enhancing
the activated state of the integrin receptor enhanced PDGFR-bFig. 4. Inhibiting PDGFR enhances integrin 2b expression while
activating integrin enhances PDGFR-b phosphorylation. Panel (A)
depicts integrin 2b expression following treatment with RA plus or
minus AG1296 for 48 h. Panel (B) shows PDGFR-b Y1021 phos-
phorylation in HL-60 cells following treatment with RA plus or minus
integrin aMb2 ligand for 72 h. Shown are means with error bars
representing standard errors of means from three independent exper-
iments. The insert shows PDGFR-b Y1021 phosphorylation histo-
grams for a typical experiment. (*) indicates treatment groups that
were signiﬁcantly diﬀerent from control and (#) indicates RA plus
AG1296 treated groups that were signiﬁcantly diﬀerent from cells
receiving RA only. C, control; A, 10 lM AG1296; R, 2 lM retinoic
acid; R + A, 10 lM AG1296 plus 2 lM retinoic acid; L, 5 lM integrin
aMb2 ligand; R + L, 5 lM integrin aMb2 ligand plus 2 lM retinoic
acid.
Fig. 5. Inhibiting PDGFR simultaneously with RA induced diﬀeren-
tiation enhances endothelium mobility. HL-60 cells were treated with
RA in the absence or presence of 10 lM AG1296 for 72 h. A total of 2
million HL-60 cells in 2 ml of fresh media were pipetted on a
monolayer of EAhy926 endothelial cells that were grown in a six well
plate for 72 h, wounded with a pipette tip and washed extensively with
PBS prior to addition of HL-60 cells. Following 24 h of co-culture, the
cell suspension was removed, the endothelial layer was washed with
PBS at 37 C. One milliliter of the warm PBS was added to the wells in
order to take the pictures. (A) shows endothelial cell migration, in a
representative experiment, after exposure to control, AG1296, RA, or
RA plus AG1296 treated HL-60 and (B) presents the quantization
resulting from three independent experiments.phosphorylation but inhibiting the PDGFR using AG1296 en-
hanced the expression of integrin b2.
3.5. AG1296 in conjunction with retinoic acid increases the
mobility of endothelial cells
Treating the leukemic HL-60 with PDGFR inhibitor AG-
1296 along with RA caused increased endothelial cell motility,
a feature of the lung capillary leak. RA- or AG1296-treated
HL-60 cells tended to increase endothelial motility compared
to the motility induced by the control HL-60, however statisti-
cal signiﬁcance was not reached (P = 0.08 when comparing
control to RA treated cells). The motility induced by both
agents is signiﬁcantly higher than the mobility induced by the
control HL-60 (P = 0.002) or by the RA alone (P = 0.03) –
Fig. 5.4. Discussion
Here we report that the presence of the PDGFR inhibitor
AG1296 increases signs of RAS and that the eﬀects seen with
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interaction of the PDGFR receptor with the integrin receptor
signaling pathway.
A negative cross talk between the PDGFR and adhesion has
been suggested before. For example, it was reported that cell
adhesion induces ubiquitin-mediated degradation of the
PDGFR-b [12]. Zaslavsky et al. found that spingosin-1-phos-
phate induced cell detachment in HEK293 cells which could
be reversed by AG1296 or engaging b1 integrin into an active
state [13]. The precise mechanism of the PDGFR – integrin
cross talk is not known. However, growth factors, such as
the macrophage colony-stimulating factor and the hepatocyte
growth factor have been reported to induce inside-out signal-
ing of integrins via their intracellular tails [14].
Using a ligand that stabilizes the active form of aMb2 inte-
grin we found a distinct eﬀect of integrin signaling during mye-
loid diﬀerentiation. Integrins have been implicated in the
diﬀerentiation of cell types that are adhesion dependent. For
example, the diﬀerentiation of myoﬁbroblasts [15] and chon-
drocytes [16] has been shown to be dependent on integrin sig-
naling. The role of the integrin in the diﬀerentiation of non-
adherent cells is less obvious. However in the hematopoetic lin-
age the integrin receptor has been found to be important in
regulating the diﬀerentiation of monocytes to macrophages
[17] and CD16 positive monocytes to osteoclasts [18]. Because
some diﬀerentiation markers, such as inducible oxidative
metabolism and CD11b expression were enhanced while some,
such as CD38 expression and G0/G1 arrest were marginally af-
fected in the presence of the integrin ligand, we can not assume
that integrins by themselves are instrumental during RA-in-
duced myeloid diﬀerentiation. Rather, integrin signaling might
interfere with or enhance certain aspects of the diﬀerentiation
program.
As for the eﬀect of the integrin ligand, we believe that the
PDGFR signaling is interfering with RA-induced myeloid dif-
ferentiation that results in the upregulation of diﬀerentiation
markers such as CD11b or oxidative metabolism. The net ef-
fect however, appears to increase signs of RAS. Here we report
that inhibiting the PDGFR with AG1296 during RA-induced
diﬀerentiation increases integrin CD18 and MMP-9 expres-
sion. CD18 on neutrophils can ﬁrmly bind to ICAM-1 on
endothelial cells [19]. MMP-9 is a metalloproteinase capable
of basement membrane degradation and hence facilitates neu-
trophil migration through the endothelium (reviewed in [20]).
The overall eﬀect of PDGFR inhibitor and RA coadministra-
tion is an increased attachment of the activated neutrophils to
the endothelium and an increased cell mobility for the endo-
thelium. AG1296 enhances the expression and secretion of
cytokines TNF-a and IL-8, both of which have been impli-
cated in RAS [4]. These cytokines act on endothelial cells,
causing them to express adhesion molecules that neutrophils
subsequently bind to. Here we show that endothelial cells ex-
posed to HL-60 cells receiving AG1296 during RA-mediated
myeloid diﬀerentiation had elevated ICAM-1 expression levels.
ICAM-1 is one of the main integrin ligands involved in leuko-
cyte transendothelial migration. It also acts as a signal trans-
ducer leading to actin cytoskeleton remodeling in endothelial
cells which in turn facilitates neutrophil invasion [5]. Collec-
tively these could contribute to the pathology of RAS.
The platelet derived growth factor receptor (PDGFR) has
now been implicated in a variety of cancers and leukemias
[21–24] and is targeted by pharmaceuticals such as imatinibmesylate (Gleevec), an inhibitor of the PDGFR family, Abl
and Arg tyrosine kinases [25]. The data of this study indicate
that the presence of PDGFR inhibitors during diﬀerentiation
induction therapy in APL might increase the risk of the patient
to suﬀer from RAS that are mediated through enhanced adher-
ence of neutrophils to endothelial cells, cytokine expression
and invasion of the endothelium.
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